<?xml version="1.0" encoding="UTF-8"?><article>
  <article-id pub-id-type="internal">13585</article-id>
  <article-id pub-id-type="doi">10.30848/PJB2026-8(4)</article-id>
  <article-title>&lt;p&gt;
	Selective cytotoxic and pro-apoptotic effects of &lt;em&gt;Cecropia pachystachya &lt;/em&gt;Tr&amp;eacute;cul in human lung cancer cells&lt;/p&gt;
</article-title>
  <contrib-group><contrib><name><string>Arina Lázaro Rochetti, Pedro Luiz Porfírio Xavier, Pedro Ratto Lisboa Pires, Claudia Do Carmo Maquiaveli, Edson Roberto Da Silva, Alia Gul, Talal Jamil Qazi and Heidge Fukumasu</string></name></contrib></contrib-group>
  <abstract>&lt;p style=&quot;text-align: justify;&quot;&gt;
	&lt;em&gt;Cecropia pachystachya Tr&amp;eacute;cul, also known as embauba of the family Urticaceae, is traditionally used in Brazilian medicine to manage diabetes, asthma, and cough.&lt;/em&gt; Previous studies have highlighted its diverse biological activities, including anti-inflammatory, cardiotonic, leishmanicidal, antidepressant-like, antioxidant, and antinociceptive effects. However, its antineoplastic potential remains unexplored. This study investigated the cytotoxic and apoptotic effects of &lt;em&gt;C. pachystachya&lt;/em&gt; extract (CPE) on human lung cancer cell lines (H460, A549, and H2023) and non-tumorigenic human foreskin fibroblasts (BJ cells). The extract exhibited concentration-dependent cytotoxicity across all cancer cell lines while sparing non-cancerous BJ cells. Further analyses using acridine orange/ethidium bromide (AO/EB) staining indicated that the observed cytotoxicity was mediated through the induction of apoptosis rather than necrosis. Liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) analysis identified chlorogenic acid (48%) and orientin (2.9%) as the major constituents of CPE. These findings suggest that &lt;em&gt;C. pachystachya&lt;/em&gt; harbors bioactive compounds with selective anticancer properties, highlighting its potential as a promising candidate for the development of novel anticancer therapeutics.&lt;/p&gt;
&lt;p&gt;
	&amp;nbsp;&lt;/p&gt;
</abstract>
  <publication-status>Published</publication-status>
  <year>2026</year>
  <volume>58</volume>
  <issue>8</issue>
  <pages-from>1833</pages-from>
  <pages-to>1839</pages-to>
</article>
